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OBJECTIVE — To assess the effect of three premeal timings of rapid-acting insulin on post-
prandial glucose excursions in type 1 diabetes.
RESEARCH DESIGN AND METHODS — Ten subjects participated in a three-way
randomized crossover trial. Mean  SD age was 45.5  12.1 years, A1C was 8.55  1.50%,
duration of diabetes was 23.8  7.8 years, and duration of continuous subcutaneous insulin
infusion therapy was 8.5  6.1 years. Insulin aspart was administered at 30, 15, or 0 min before
mealtime.
RESULTS — Area under the curve was lower in the 15 stratum (0.41  0.51 mmol/l/min)
than that in the 30 stratum (1.89  0.72 mmol/l/min, P  0.029) and 0 stratum (2.11  0.66
mmol/l/min, P  0.030). Maximum glucose excursion was lower in the 15 stratum (4.77 
0.52mmol/l)thanthatinthe30(6.480.76mmol/l,P0.025)and0stratum(6.930.76
mmol/l,P0.022).Peakglucoselevelwaslowerinthe15stratum(9.260.72mmol/l)than
thatinthe30stratum(11.740.80mmol/l,P0.007)andthe0stratum(12.290.93,P
0.009). Time spent in the 3.5–10 mmol/l range was higher in the 15 stratum (224.5  25.0
min)thanthatinthe0stratum(90.523.2min,P0.001).Therewasnosigniﬁcantdifference
in occurrence of glucose levels 3.5 mmol/l between strata (P  0.901).
CONCLUSIONS — Administration of rapid-acting insulin analogs 15 min before mealtime
results in lower postprandial glucose excursions and more time spent in the 3.5–10.0 mmol/l
range, without increased risk of hypoglycemia.
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O
ne of the most challenging aspects
of attaining adequate glycemic con-
trol is limiting the postprandial
raiseofglucose.CurrentAmericanDiabe-
tes Association guidelines recommend
aiming for postprandial blood glucose
levels 10 mmol/l (1,2). With the advent
of rapid-acting insulin analogs (insulin
lispro, aspart, and glulisine), individuals
with diabetes can attain lower postpran-
dial glucose excursions (3–5). Therefore,
because of the possibility of giving the
dose of insulin at mealtime rather than
15–30minbeforethemeal,aswasrecom-
mended for human insulin (6), rapid-
acting insulin analogs have become the
preferred mealtime insulin for people
with type 1 diabetes (7,8).
Afterameal,thepostprandialglucose
peak mostly occurs between 1 and 2 h
with a mean peak time of 75 min (9).
Rapid-acting insulin analogs display a
maximum effect at 100 min after sub-
cutaneous injection (10). Thus, the ques-
tion arises whether perhaps it would be
better to inject the mealtime insulin 15 or
even 30 min before the start of a meal. In
this way the insulin peak action is better
synchronized with the glycemic excur-
sions after a meal, thereby potentially
minimizingtheheightofthepostprandial
glucose excursions. Limited data address
this topic. The aim of this study was to
measure the effect of different premeal
timing of rapid-acting insulin on post-
prandial excursions.
RESEARCH DESIGN AND
METHODS— Subjectswererecruited
fromacohortofpatientswillingtopartic-
ipate in scientiﬁc research at the Depart-
ment of Internal Medicine at the
Academic Medical Centre in Amsterdam,
the Netherlands. The protocol was ap-
proved by the medical ethics committee,
and all subjects signed a consent form.
The study was performed in concordance
with the Declaration of Helsinki.
Ten people with type 1 diabetes were
included in this study. All patients met
theinclusioncriteria,treatmentwithcon-
tinuous subcutaneous insulin infusion
(CSII) therapy for at least 6 months, du-
ration of diabetes of at least 2 years, and a
BMI 35 kg/m
2. All patients were treated
withinsulinaspart,andfourpatientswho
were treated with insulin lispro switched
to insulin aspart for the duration of this
trial.
The study consisted of three visits for
each subject. On the day before the 1st
study day, patients were provided with a
subcutaneous continuous glucose moni-
toring (CGM) sensor (Sof-Sensor,
MedtronicDiabetes,Northridge,CA)and
were instructed to calibrate the sensor at
home according to the manufacturer’s
speciﬁcations. Patients received a tele-
phone number with 24-h availability for
assistance on problems with the sensor
(e.g., alarms or help with calibration) and
returned home for the night.
At each visit, insulin to cover break-
fast was administered using the patient’s
insulin pump. The size of the insulin bo-
lus was determined by the patient with
their usual carbohydrate-to-insulin ratio.
Patientswererandomlyassignedeachday
by means of sequentially numbered
opaque, sealed envelopes to insulin bolus
administration at 30, 15, or 0 min before
the meal using a cross-over design. On
each study day patients reported fasting
to the clinical research unit and received
an intravenous catheter in the antecubital
vein for blood collection. Before the start
of the study protocol blood glucose was
measured by ﬁnger prick (OneTouch Ul-
tra; Lifescan, Milpitas, CA). If blood glu-
cosewasbetween3.5and7.8mmol/l,the
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diately. If blood glucose was higher, insu-
linaspartwasadministeredintravenously
according to the following formula (11):
insulin aspart intravenous dose  (mea-
sured blood glucose  target blood glu-
cose)/(100/daily insulin dose in inter-
national units).
If blood glucose had been corrected
to range and remained stable (excursions
0.6mmol/lover1h),thestudyprotocol
commenced. If blood glucose was too
low, patients would not start the study
protocolandwereaskedtoreturnanother
day.
Each patient was provided with a
breakfast comparable to their regular
breakfast. The meal for an individual pa-
tient was identical for all study days.
Blood was sampled every 15 min during
1 h before the meal, every 10 min during
the ﬁrst 2 h after the meal, and every 20
min during the 3rd and 4th h after the
meal. Blood samples were collected in
2-ml sodium ﬂuoride tubes for determi-
nation of blood glucose. Patients would
go home 4 h after the test meal while con-
tinuing to wear the CGM sensor and re-
ported back to the clinical research unit
the following days to complete the study.
At the end of the 3rd study day, the CGM
sensor was removed, and the sensor data
were plotted against the venous blood
glucose.
The area under the curve (AUC) was
calculated (trapezoid method) using as a
baseline the mean values of the ﬁrst three
blood glucose values before insulin ad-
ministration. The primary outcome mea-
sure was the AUC for the blood glucose
values from the start of the meal until 4 h
afterward. Secondary outcome measures
were the AUC for the sensor glucose val-
ues, the maximum glucose excursion
from baseline, the peak glucose value, the
number of hypoglycemic episodes de-
ﬁned as glucose values 3.5 mmol/l, and
total time spent in euglycemia, deﬁned as
the time spent in the glucose range be-
tween 3.5 and 10.0 mmol/l.
Outcome measures were analyzed for
signiﬁcance (P  0.05) using SPSS 17.0
(SPSS, Chicago, IL). A repeated-measures
ANOVA was performed for all outcome
measures. When the repeated-measures
ANOVA indicated an overall signiﬁcant
difference among treatment arms, a
paired samples t test was performed be-
tween treatment arms. Categorical vari-
ables were analyzed using the 
2 test or
Fisher exact test. Data are presented as
means  SEM, means  SD, and
frequency.
RESULTS— All participants, three fe-
males and seven males, completed the
three study visits. Mean  SEM age was
45.5  12.1 years. A1C was 8.55 
1.50%, duration of diabetes was 23.8 
7.8 years, and duration of CSII therapy
was8.56.10years.Themeancarbohy-
drate content of the meal was 48.02 
6.23 g. The mean size of the insulin bolus
was 6.03  0.60 IU. There was no signif-
icant difference in blood glucose levels
(mean  SEM) at the start of the study
among treatment arms (7.00  0.55
mmol/l for the 0 treatment arm, 6.64 
0.41 mmol/l for the 15 treatment arm,
and 7.05  0.59 mmol/l for the 30
treatment arm, P  0.749), nor was there
any difference among treatment arms for
the need for an intravenous insulin infu-
sion to get glucose within the predeﬁned
rangeuponadmittance(threetimesinthe
0 treatment arm, three times in the 15
treatment arm, and three times in the
30 treatment arm, P  1.000). Patients
reported with a blood glucose value 3.5
mmol/l on all study days. According to
CGM values, no patient experienced noc-
turnal hypoglycemia on the night before
an experiment. Figure 1 shows the aver-
aged blood glucose values from the start
of the study protocol until the end of the
studydaypertreatmentarm.Primaryand
secondaryoutcomemeasuresaresumma-
rized in Table 1 for both blood glucose
and CGM data. The 15 treatment arm
had a signiﬁcantly lower AUC of 0.41 
0.51 mmol/l/min than the 0 treatment
arm at an AUC of 2.11  0.66 mmol/l/
min (P  0.030) and the 30 treatment
arm, which had a AUC of 1.89  0.72
mmol/l/min (P  0.029). There was no
signiﬁcant difference in AUC between the
30 and 0 treatment arm (P  0.785). In
a post hoc analysis for differences in AUC
among treatment arms in subgroups ac-
cording to A1C level above or below the
median and fasting blood glucose above
or below the mean, no signiﬁcant overall
differences among treatment arms could
be detected; however, the AUC of the
15treatmentarmremainedthesmallest
among the three treatment arms (data not
shown).
The 15 treatment arm had a signif-
icantly lower glucose excursion (4.77 
0.52 mmol/l) than the 0 treatment arm
(6.93  0.76 mmol/l, P  0.022) and
30treatmentarm(6.480.76mmol/l,
P  0.025). The 15 treatment arm had
signiﬁcantly lower maximum blood glu-
cose values (9.26  0.72 mmol/l) than
the 30 treatment arm (11.74  0.80
mmol/l, P  0.007) and the 0 treatment
arm (12.29  0.93 mmol/l, P  0.009).
There was no signiﬁcant difference be-
Figure1—Bloodglucoseduringmealtimewithdifferenttimingofinsulinbolus.Theﬁgureshows
meanSEMbloodglucosevaluesbeforeandafterameal(M).Thetimingoftheinsulinboluswas
30 min before the meal (Œ), 15 min before the meal (f), and directly at the start of the meal (F).
The AUC, maximum excursion, and maximum blood glucose values are all signiﬁcantly lower in
the 15 treatment arm. The number of minutes in the 3.5–10 mmol/l glucose range is also
signiﬁcantly increased in the 15 treatment arm.
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0.456).
Timespentineuglycemiawashighest
in the 15 treatment arm (224.5  25.0
min), not signiﬁcantly different from that
for the30 treatment arm (182.528.2
min, P  0.212) but signiﬁcantly higher
than that for the 0 treatment arm (90.5 
23.2min,P0.000).Comparedwiththe
0 treatment arm, the 15 treatment arm
had a 80.6% lower AUC, 31.2% lower
maximum blood glucose excursion,
24.7% lower maximum blood glucose
value,and148.1%moretimespentineu-
glycemia. There was no signiﬁcant differ-
ence between the occurrence of
hypoglycemia deﬁned as a blood glucose
value 3.5 mmol/l among treatment
arms.Allhypoglycemicvalueswerenoted
afterward in the laboratory report, not
from the ﬁnger prick measurements dur-
ing the study. None of the hypoglycemic
values occurred before the start of the
meal, and no rescue carbohydrates were
administered during the entire duration
of the study.
Whenwelookedattheoutcomemea-
sures using the data from the CGM de-
vice, no signiﬁcant differences among
treatment arms could be found in AUC
(30 treatment arm 2.32  0.59 mmol/
l/min, 15 treatment arm 1.10  0.11
mmol/l/min, and 0 treatment arm 1.89 
0.34 mmol/l; P  0.088), maximum glu-
cose values (P  0.174), and maximum
blood glucose excursions (P  0.537).
The overall mean absolute difference
(MAD) from sensor values relative to the
blood glucose values was 23.5  1.0%.
When MAD was divided into baseline
MAD (the hour before administration of
insulin) and postprandial MAD (the ﬁrst
4 h after the meal), there was a trend to-
ward increased MAD postprandially from
18.6  1.6% in the baseline period to
22.8  1.1% in the postprandial period
(P  0.088). It should be noted that for
this subanalysis data from study days on
which patients had received an intrave-
nous insulin correction bolus were dis-
carded (9 of 30 study days).
CONCLUSIONS— This study tested
the hypothesis that earlier administration
of a mealtime bolus of rapid-acting insu-
lin would lower postprandial glucose ex-
cursions. We found administration of
insulin 15 min before a meal to be opti-
mal; it signiﬁcantly lowered the AUC, the
postprandial maximum blood glucose
value, and the maximal blood glucose ex-
cursionby80.6,24.7,and31.2%,respec-
tively. The administration of insulin 15
min before the meal led to signiﬁcantly
more time spent in euglycemia (3.5–10
mmol/l)thanadministrationatthestartof
ameal.Inaddition,thesebeneﬁcialeffects
were not accompanied by an increase in
the occurrence of hypoglycemia. As can
be seen in Fig. 1, however, the blood glu-
cose declines slightly before mealtime
wheninsulinisadministeredat15min.
This ﬁnding implies that it might be pru-
dent to administer insulin at this time
only when preprandial glucose levels are
5.0 mmol/l. This study did not show
any signiﬁcant difference in AUC, maxi-
mumbloodglucoseswing,andpostpran-
dialmaximumbloodglucosebetweenthe
30 and 0 treatment arms, although an
initial decline was noticeable in the 30
min treatment arm.
An earlier study by Cobry et al. (12),
which tested the effect of insulin given 20
min before the meal, at the start of the
meal, and 20 min after the meal, also
found signiﬁcantly better postprandial
glucose control with insulin injection 20
min before the meal. In addition, a study
in a pediatric population by Scaramuzza
et al. (13) tested the effect of timing of
mealtime insulin. Thus study also dem-
onstrated a signiﬁcant difference in 1-h
postprandial glucose levels, which were
signiﬁcantly higher when the insulin bo-
lus was administered after the meal and
lowest when insulin was administered 15
min before the meal. However, there was
no signiﬁcant difference in AUC among
treatment arms. Thus, three studies argue
forinsulininjection15–20minbeforethe
meal,withourstudyarguingagainsteven
earlier administration at 30 min before
the meal.
We can only speculate on the reason
that, in this study, insulin administration
at30mindidnotimprovepostprandial
glycemic control compared with that in
the0treatmentarm.Onecouldarguethat
if insulin administration at 15 min before
the meal is the optimum, then both 30
and0treatmentarmshadanequal15min
mismatch with the optimum, resulting in
almost equal postprandial glycemic con-
trol.Furtherresearchisneeded,however,
to support this hypothesis.
During this study we ﬁtted every pa-
tientwithaCGMsensor.Withuseofsen-
sor data alone, we could not demonstrate
anysigniﬁcantchangesamonginsulinad-
ministration times. We hypothesize that
this result is due to the fact that sensor
accuracy is worse with rapid increases
anddecreasesinbloodglucoseandthere-
fore tends to underreport the changes in
glucose levels. This hypothesis is sup-
ported by analyses of CGM accuracy by
Breton et al. (14), who concluded that
there is a correlation between rate of
Table 1—Summary of results for blood glucose and CGM data
Treatment
arm 30
Treatment
arm 15
Treatment
arm 0
Overall P value
(repeated-measures ANOVA)*
Blood glucose–derived outcomes
AUC (mmol/l/min) 1.89  0.72 0.41  0.51 2.11  0.66 0.043†
Maximum glucose excursion (mmol/l) 6.48  0.76 4.77  0.52 6.93  0.76 0.038†
Peak glucose level (mmol/l) 11.74  0.80 9.26  0.72 12.29  0.93 0.003†
Time spent in euglycemia (min)‡ 182.5  28.2 224.5  25.0 90.5  23.2 0.000†
Hypoglycemic events (no. of measurements)§ 6 of 220 7 of 220 4 of 220 0.901
CGM–derived outcomes
AUC (mmol/l/min) 2.32  0.59 1.10  0.11 1.89  0.34 0.088
Maximum glucose (mmol/l) 11.48  1.08 10.11  0.59 11.31  0.82 0.174
Maximum glucose excursion (mmol/l) 5.24  1.01 4.37  0.64 5.41  0.67 0.537
Data are means  SEM. *Signiﬁcance between treatment arms when repeated-measures ANOVA indicated an overall signiﬁcant difference among treatment arms
isgivenin RESULTS.†Resultsaresigniﬁcantlydifferentamonggroups.‡Deﬁnedasbloodglucosevaluesbetween3.5and10mmol/l.§Deﬁnedasbloodglucosevalues
3.5 mmol/l.
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alsofoundthatatapositiverateofchange
ofbloodglucose,theCGMsensortendsto
readlowerglucosevalues.Incontrast,ata
negative rate of change, the CGM sensor
tendstoreadhigherglucosevalues.Thus,
the CGM sensor has a tendency to report
ﬂattened out postprandial excursions.
The MAD of the sensor during our study
was relatively high at 23.5  1.0% com-
pared with other published MAD values,
with a trend toward the highest MADs in
thepostprandialperiod,conﬁrmingcom-
promised sensor accuracy during the
postprandial rapid rise and fall in glucose
(15).
The data from this study could also
prove valuable for use in closed-loop sys-
tems,inwhichdealingwiththepostpran-
dial glucose excursions is one of the main
challenges (16). According to our data re-
garding the effect of timing of insulin ad-
ministration, an argument can be made
for mealtime announcement by patients
wearing future closed-loop devices,
should these devices use current rapid-
acting insulin analogs administered via
CSII.
Administrationofrapidactinginsulin
analogs 15–20 min before the meal im-
proves postprandial glucose control but
will require added vigilance of patients.
Thus, larger trials outside the clinical re-
search center are needed before this rec-
ommendation is incorporated in clinical
guidelines.
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